Myeloperoxidase aids prognostication together with NT-BNP In high-risk patients with acute ST elevation myocardial infarction

Sohail Q Khan ^1*, Dominic Kelly ¹, Pauline Quinn ¹, Joan E Davies ¹ and Leong L Ng ¹

¹ University of Leicester, United Kingdom

^* To whom correspondence should be addressed. E-mail: sqk1{at}le.ac.uk.

Accepted 7 November 2006

Abstract

Background Inflammation plays a critical role in acute myocardial infarction. One such inflammatory marker is myeloperoxidase (MPO). Its role as a predictor of death or MI in patients with ST segment elevation myocardial infarction (STEMI) is unclear. We sought to investigate this and compared it to N terminal pro B type natriuretic peptide (NT-BNP).

Method We studied 384 post STEMI patients. Patients were followed-up for the combined endpoint of death or readmission with non-fatal MI.

Results There were 40 deaths and 37 readmissions with MI. Median MPO was raised in patients experiencing death or MI compared to survivors (median [range] ng/ml, 50.6[15.3-124.1] vs. 33.5[6.6-400.2], p=0.001). Using a Cox proportional hazards model log median MPO (HR 6.91, 95% CI: 1.79-26.73, p=0.005) and log median NT-BNP (HR 4.21, 95% CI: 1.53-11.58, p=0.005) independently predicted death or non-fatal MI. MPO had predictive power in both below and above median NT-BNP levels (log rank 5.60, p=0.020, log rank 5.12, p=0.024 respectively). The receiver-operating curve for median NT-BNP yielded an area under the curve (AUC) of 0.72 (95% CI: 0.65-0.79, p<0.001); for median MPO the AUC was 0.62 (95% CI: 0.55-0.69, p=0.001). The logistic model combining the 2 markers yielded an AUC of 0.76 (95% CI: 0.69-0.82, p<0.001).

Conclusion MPO and NT-BNP may be useful tools for risk stratification of all acute coronary syndromes, including higher risk STEMI patients.

Keywords: Myocardial infarction, myeloperoxidase, peptides, prognosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Wong, N. D., Gransar, H., Narula, J., Shaw, L., Moon, J. H., Miranda-Peats, R., Rozanski, A., Hayes, S. W., Thomson, L. E.J., Friedman, J. D., Berman, D. S. (2009). Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events. J Am Coll Cardiol Img 2: 1093-1099 [Abstract] [Full Text]  
• Schindhelm, R. K., van der Zwan, L. P., Teerlink, T., Scheffer, P. G. (2009). Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?. Clin. Chem. 55: 1462-1470 [Abstract] [Full Text]  
• Nicholls, S. J., Hazen, S. L. (2009). Myeloperoxidase, modified lipoproteins, and atherogenesis. J. Lipid Res. 50: S346-S351 [Abstract] [Full Text]  
• Rudolph, T. K., Rudolph, V., Baldus, S. (2008). Contribution of Myeloperoxidase to Smoking-dependent Vascular Inflammation. Proc Am Thorac Soc 5: 820-823 [Abstract] [Full Text]  
• Riccioni, G., Capra, V., D'Orazio, N., Bucciarelli, T., Bazzano, L. A. (2008). Leukotriene modifiers in the treatment of cardiovascular diseases. J. Leukoc. Biol. 84: 1374-1378 [Abstract] [Full Text]  
• Gandley, R. E., Rohland, J., Zhou, Y., Shibata, E., Harger, G. F., Rajakumar, A., Kagan, V. E., Markovic, N., Hubel, C. A. (2008). Increased Myeloperoxidase in the Placenta and Circulation of Women With Preeclampsia. Hypertension 52: 387-393 [Abstract] [Full Text]  
• Tang, W.H. W., Francis, G. S. (2007). The Year in Heart Failure. J Am Coll Cardiol 50: 2344-2351 [Full Text]